Kornimate/medical-research-clean huggingface dataset:
"it is a real" the first baby of autologous stem cell therapy in premature ovarian failure

Conditions: Premature Ovarian Failure

Summary: the purpose of this work is to evaluate the therapeutic potential of autologous mesenchymal sc (msc) therapy in women suffering from pof.

stem cells (sc) are the foundation cells for every organ, tissue and cell in the body. they are self sustaining and can replicate themselves for long periods of time. they have the remarkable potential to develop in many different cell types in the body. premature ovarian failure (pof) is the loss of ovarian function in women less than 40 years. it is associated with sex steroid deficiency, amenorrhea, infertility, and elevated serum gonadotropins. this work aimed to evaluate the therapeutic potential of autologous mesenchymal sc (msc) transplantation in women suffering from pof. out of 112 high risk patients for pof, 10 cases were diagnosed as pof. the ten pof patients were scheduled for msc transplantation at al- azhar university hospitals. msc preparation from the bone marrow of the iliac crest was laparoscopically injected in the ovaries. endometrial fractional biopsy is histopathologically (hp) and immunohistochemically (ih) stained and evaluated according to edessy stem cells score (ess) (1).

Eligibility criteria:
inclusion criteria: * post-menarche female less than 40 years old. * normal karyotyping female. * primary ovarian failure females * follicle-stimulating hormone (fsh) more than or equal to 20 iu/l. * agree to sign the designed consent for the study. exclusion criteria: * autoimmune diseases. * breast cancer, ovarian cancer. * hypersensitivity to any gonadotropin-releasing hormone (gnrh) analogs. * those with major medical problems such as malignancy, hepatitis, etc.

Keywords: pof ess stem cell therapy
microbiome and association with implant infections

Conditions: Breast Cancer; Breast Cancer Female; Genetic Predisposition to Disease

Summary: the most common tissue expander-related infections are from staphylococcus and pseudomonas species. in addition, from breast tissue microbiome studies, staphylococcus and pseudomonas show variable abundance across samples. the investigator hypothesizes that participants undergoing mastectomy with high initial abundance of staphylococcus and/or pseudomonas are more likely to develop subsequent tissue expander-related infections from these respective organisms.

primary objective: i. to determine the feasibility of breast microbiome sampling using the study techniques secondary objectives: i. to define the differences in the gut and breast microbiomes between participants undergoing mastectomy with implant-based reconstruction who develop post-operative implant infection and those who do not. ii. to determine the effects of post-operative antibiotics on the gut and breast microbiomes after mastectomy with implant-based reconstruction. outline: participants are randomized to 1 of 2 cohorts. cohort a: participants receive postoperative antibiotics to take for at least 7 days post-operatively. cohort b: participants receive no antibiotics post-operatively in the absence of clinical evidence of infection. participants are followed up for 90 days.

Eligibility criteria:
inclusion criteria: 1. patients must have histologically confirmed breast malignancy or genetic predisposition to breast cancer. 2. age \>= 18 years 3. scheduled to undergo mastectomy with the immediate placement of tissue expanders or implant placement 4. ability to understand a written informed consent document, and the willingness to sign it 5. at least 4 weeks post-completion of chemotherapy or radiation therapy. exclusion criteria: 1. any significant medical condition or laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study 2. pregnant or breastfeeding 3. patients who have taken antibiotics within 90 days of the consent date 4. patients who have taken probiotics within 90 days of the consent date 5. patients who have a documented or reported allergic reaction to the outlined antibiotics to be used in this study 6. male patients

Keywords: post-surgical antibiotics breast implant infections breast microbiome breast reconstruction mastectomy
effect of rapeseed oil and sunflower oil

Conditions: Familial Hypercholesterolemia

Summary: familial hypercholesterolemia (fh), an inherited disorder of lipoprotein metabolism, is a risk for early cardiovascular disease (cvd). this autosomal dominant disease is characterized by markedly elevated plasma concentrations of low density lipoprotein (ldl) and total cholesterol (tc). the purpose of this study is to compare the effect of a diet low in saturated fats but enriched either with rapeseed oil (ro) or sunflower oil (so) in children and adolescents with fh on serum lipoproteins.


Eligibility criteria:
inclusion criteria: * chilren and adolescents between 6 and 18 years of age * ldlc \> 130 mg/dl and * tc \> 200 mg/dl * 7 day nutrition record * written informed consent exclusion criteria: * overweight * underweight * mental disability * drug therapy
exploring the acceptability and efficacy of a transdiagnostic treatment for misophonia

Conditions: Misophonia

Summary: despite increasing recognition of misophonia, there are currently no evidence-based treatments to help those who are suffering. therefore, the primary purpose of this study is to assess the acceptability, feasibility, and preliminary efficacy of a treatment for misophonia. this study will be conducted in two phases. in the phase 1, participants will receive a treatment the investigators believe can help manage symptoms of misophonia: the unified protocol. this treatment uses evidence-based psychological principles (e.g., managing attention or behavior) in a flexible manner and will focus on developing skills to help reduce the distress and impairment associated with misophonia. after treatment, patients will provide feedback about their experience. the investigators will use this feedback to revise the treatment as indicated. in phase 2, participants will receive the revised treatment and provide feedback on their experience. throughout treatment in either phase, participants will provide daily and weekly information about their symptoms. the aims of this study are (1) to explore the acceptability and feasibility of the unified protocol for individuals who experience misophonia and (2) to examine whether this treatment helps reduce symptoms associated with misophonia.


Eligibility criteria:
inclusion criteria: * between age 18-65 * able to read english * meet criteria for interfering symptoms of misophonia * live in north carolina exclusion criteria: * under age 18 or over age 65 * current mania * current psychotic disorder * current anorexia * presents with a condition that requires immediate prioritization in treatment (e.g., suicide planning or intent) phase 1 participants cannot also participate in phase 2.

Keywords: misophonia treatment
effect of treatment with systane ultra in symptomatology and visual task efficiency in digital device users

Conditions: Digital Eye Strain; Computer Vision Syndrome; OSDI

Summary: this study assessed the effect of one month of use of preservative-free artificial tears (systane ultra ud, alcon) on symptomatology related to digital eye strain (des), visual task performance, and tear film stability in visual display terminal users.

visual display terminal users (\>4h/day) with des (cvss17 score: ranged 29 to 42) and dryness (osdi score: ranged 13 to 24) symptomatology were prescribed with preservative-free artificial tears (systane ultra ud, alcon) four times a day for one month collecting osdi and cvss17 questionnaires in four visits \[screening (day -7), initial (day 0), one week (day 7) and one month (day 30)\]. blink rate and number of eye fixations (collected with eye-tracker) in six simple computer tasks and out-loud reading speed were determined before and after performing all tasks on the computer. tear film stability and ocular parameters were also measured.

Eligibility criteria:
inclusion criteria: * volunteer subjects of legal age will be included who agree to participate in the study after being informed by the researcher, receiving the information sheet and signing the informed consent. * eye discomfort related to dryness (osdi score ranged from 13 to 24) * symptomatic digital device users (cvss17 score ranged from 29 to 42 points - stages 3 and 4) * use of computer continuously for at least 4 hours per day (work week) * good best-corrected visual acuity (visual acuity logmar ≤ 0.00 for distance, intermediate (60cm) and near (40cm)) exclusion criteria: * systemic administration of drugs with a possible effect on the ocular surface. * topical administration of any drugs that can alter the ocular surface. * use of contact lenses * use of artificial tears or lubricants at least 7 days before inclusion in the study (recruitment visit). * any other ocular pathology or binocular conditions which may cause discomfort (e.g. heterophoric, accommodative, and eye movement disorders)
cosmetic study to improve the appearance of skin afflicted with mild to moderate atopic dermatitis.

Conditions: Atopic Dermatitis Eczema

Summary: the purpose of this study is to observe the performance of a cosmetic product, ao+mist, on the appearance of arm skin in subjects with atopic dermatitis

this is a single center, double-blind, bilateral, placebo-controlled study in subjects with atopic dermatitis affecting both sides of the body. up to 20 subjects will be enrolled to participate. subjects will undergo a 2 week washout period prior to the baseline procedure. follwoing the baseline visit assessments, subjects will be asked to apply "ao+ mist" or placebo to the affected area of the arm twice a day (morning and night) for 30 days. after the 30 day initial study period, subjects will automatically be rolled over to participate in the extension of the trial for another 30 days using only ao+mist on the body parts affected by atopic dermatitis.

Eligibility criteria:
inclusion criteria: 1. male and female subjects ≥18 2. in good general health as determined by a thorough medical history i. visible flexural dermatitis ii. personal history of flexural dermatitis iii. personal history of dry skin in the past 12 months 3. subjects should have similar presentation and severity of ad on both arms 4. ability to comprehend and comply with study procedures 5. agree to commit to participate in the current protocol 6. provide written informed consent prior to any study procedure being performed (all subjects should be able to understand the informed consent form and any other documents that subjects are required to read) exclusion criteria: 1. female subjects who are pregnant or lactating or who are trying to conceive 2. any clinically relevant abnormality identified on the screening history or any other medical condition or circumstance making the volunteer unsuitable for participation in the study 3. any skin condition which in the investigator's opinion may interfere with the evaluation of atopic dermatitis 4. severe cases of ad that present with pustules and weeping and those cases that require urgent medical attention 5. treatment with any investigational drug within 30 days or 5 half-lives (whichever is longer) prior to the beginning of the screening period (this includes investigational formulations of marketed products, inhaled and topical drugs) 6. hypersensitivity to ao+mist or its components 7. seropositive for human immunodeficiency virus (hiv) by medical history review at screening 8. positive for hepatitis b virus surface antigen (hbsag) or positive hepatitis c virus antibody (hcv ab) by medical history review at screening 9. any other condition and/or situation that causes the investigator to deem a subject unsuitable for the study (e.g., due to expected test product non-compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures)
the outcome of chronic kidney disease patients with obstructive sleep apnea syndrome

Conditions: Chronic Kidney Diseases; OSAS (Obstructive Sleep Apneas Syndrome)

Summary: obstructive sleep apnea (osa) is highly prevalent in chronic kidney disease (ckd) patients and strongly linked to obesity, metabolic syndrome, and type 2 diabetes. besides elevating cardiovascular disease risk, osa may worsen renal function and diminish quality of life, making its understanding critical for ckd patient health. this study will establish a large, long-term cohort of non-dialysis ckd patients to identify osa risk factors, explore osa's association with adverse renal outcomes, and determine osa prevalence and epidemiological characteristics within the ckd population. the findings will provide a scientific foundation for early osa identification, diagnosis, and intervention in ckd patients.


Eligibility criteria:
inclusion criteria: * voluntarily sign the informed consent form; * aged ≥ 18 years and \< 75 years; * patients with ckd stages 3-4, with an egfr of 15-60 ml/min/1.73m² calculated using the ckd-epi formula for at least 3 months. exclusion criteria: * patients receiving oxygen therapy or continuous positive airway pressure (cpap) treatment; * patients with other sleep disorders, including restless legs syndrome, periodic limb movement disorder, etc.; * patients with other severe comorbidities: severe heart failure (nyha class iii or iv); myocardial infarction, unstable angina, or stroke within the past 3 months; severe arrhythmias requiring medication or device therapy; respiratory diseases, including copd, asthma, thoracic deformities, etc.; neurological disorders, including myasthenia gravis, parkinson's disease, alzheimer's disease, etc.; active liver disease or severe hepatic insufficiency; psychiatric conditions, including depression, anxiety disorders, etc.; history of malignancy within the past 5 years (except cured basal cell carcinoma); uncontrolled hyperthyroidism; * patients who underwent surgery or had acute infections within the past 3 months; * current heavy alcohol consumption:females: \>3 drinks/day or \>7 drinks/week; males: \>4 drinks/day or \>14 drinks/week (1 standard drink = 14g of alcohol) * current use of medications that may severely interfere with sleep, such as antipsychotics, antiepileptics, antiparkinsonian drugs, antidepressants, opioids, etc.; * females who are pregnant or lactating at screening or baseline; * inability to comply with the study due to: low education level, language barriers, inability to tolerate or complete sleep monitoring, or other reasons preventing completion of study procedures (e.g., follow-up); * deemed unsuitable for participation by the investigator's judgment.
fitostimoline® hydrogel versus saline gauze dressing in diabetic foot ulcers

Conditions: Diabetic Foot

Summary: diabetes mellitus (dm) is one of the most widespread metabolic diseases and the alarming rise in its prevalence worldwide poses enormous challenges. the microvascular and macrovascular complications of dm heavy impact on longevity and quality of life, and in particular diabetic foot ulcers (dfus) are among the ten top causes of worldwide disease burden and disability essential components of the standard care, management, and treatment of dfus are represented by health education, strict control of blood glucose and cardiovascular risk factors, offloading, local debridement, and adequate dressing. a wide variety of dressing is available, and these include basic contact dressings (low adherence dressings such as saline gauze, paraffin gauze or simple absorbent dressings) and advanced dressings (alginate, hydrogel, films, hydrocolloid, foam). it is important underline that due to lack of evidence from head-to-head randomized controlled trials (rcts), the relative effects of any of these dressings in dfus remain unclear. consequently, so far clinical evidence supporting the choice for either hydrogel or saline gauze dressing, has been related mostly on clinician perception rather than high quality evidence. here we evaluated the efficacy and safety of fitostimoline® hydrogel dressing versus saline gauze dressing in patients with dfus in a monocentric, two-arm, open-label, randomized, controlled trial.


Eligibility criteria:
inclusion criteria: * type 1 diabetes and type 2 diabetes, * adult patients with dfus at grades ic or iic for a period of at least 12 weeks, * an akle brachial index \>0.8, * be able to understand simple instructions, * provided voluntary, signed informed consent exclusion criteria: * active infection * evidence of ischaemia in the limb, * osteomyelitis, * gangrene, * systemic inflammatory or autoimmune disease, * use of corticosteroids, immunosuppressive agents, radiation therapy and chemotherapyan, * known hypersensitivity to any of the dressing components.

Keywords: diabetic foot dressing medication
a quality of life study re management of malignant pleural effusions

Conditions: Malignant Pleural Effusions

Summary: there is much data in the literature regarding optimal treatment approaches for malignant pleural effusions as assessed by patient outcomes. however, data on quality of life and satisfaction with treatment from the patient's perspective is not available.

this study will compare various treatment strategies in the management of malignant pleural effusions with respect to: 1. primary endpoint: the successful palliation of symptomatic pleural effusions as assessed by the london chest activity of daily living scale (lcadls) 2. secondary endpoints: i) impact of treatment on patient quality of life as assessed by the functional assessment of chronic illness therapy - palliative patient (facit-pal) questionnaire ii) assessment of patient satisfaction with treatment received via functional assessment of chronic illness therapy-treatment satisfaction (facit-ts) questionnaire iii)pleurodesis success rates assessed by 2 and 6-week effusion control rates on cxr iv) requirement of further hospitalizations or procedures for the treatment of recurrent effusions v) comparison of morbidity and mortality rates for differing treatment approaches vi) comparison of cost in a canadian health care setting for differing treatment approaches

Eligibility criteria:
inclusion criteria: * symptomatic pleural effusion * history of malignant disease * age greater that 18 years * consent to participate in study exclusion criteria: * significant ipsilateral endobronchial disease * prior ipsilateral, intra-pleural therapy, as defined by: prior chest tube placement for effusion, prior attempt at chemical/surgical pleurodesis, prior surgical pleurectomy * active pulmonary or pleural infection * granulocytes \< 1500/mm3, platelets \< 50,000/mm3 * systemic chemotherapy within 2 weeks * allergy to talc
summer harvest adventure: a garden-based obesity prevention program for children residing in low-resource communities

Conditions: Childhood Obesity

Summary: the objective of this study is to implement and test the efficacy of the "summer harvest adventure," a comprehensive garden-based behavioral, social, and environmental intervention for children (ages 8-11 years) residing in low-resource communities.

the investigators will conduct a 2-arm randomized controlled trial designed to determine the efficacy of a multifaceted obesity prevention and lifestyle intervention in low-resource children and parent/adult caregiver (pac) called "summer harvest adventure." a total of 240 children (ages 8-11 years) will be randomized to the garden-based intervention (sha) or an enhanced control group (msp). summer harvest adventure includes: 1) remote and group coaching using a focused motivational interviewing approach; 2) weekly fruit, vegetable, and herb harvesting to increase summer food access; and 3) group education for children and their families in a social setting. assessments for both groups will be collected at orientation held one week prior to the intervention (week 0), and immediately following the completion of the intervention (week 10) by trained personnel that are blinded to participants' treatment arm assignment.

Eligibility criteria:
inclusion criteria: * children 8-11 years of age (as of june 1) from assenting and consenting families * english-speaking families that agree to participate; 3) residents of snap-eligible communities in franklin county, ohio. exclusion criteria: * inability to functionally participate in harvesting; accommodations can be implemented in the future for children with special needs * communication difficulties (e.g. severe developmental delay) * lack of transportation to weekly classes or harvesting activities * non-english speakers; because coaching and classroom-based education are all conducted in english, we will of necessity restrict to english-speakers only during this phase

Keywords: obesity youth garden diet produce
impact of gonadotrophin releasing hormone analogues on oocyte and embryo quality

Conditions: Infertility, Female

Summary: the first in-vitro fertilization cycles were performed in natural unstimulated cycles. today gonadotrophins are administered to induce multiple follicular development and controlled ovarian hyperstimulation. during ovarian stimulation gonadotrophin-releasing hormone analogues are co-administered in order to prevent premature luteinizing hormone surges. premature luteinizing hormone surges are observed in about 20% of stimulated cycles without using gonadotrophin-releasing hormone analogues . avoiding the adverse effects of elevated luteinizing hormone levels, first gonadotrophin-releasing hormone agonist analogues were used to supplement the gonadotrophin stimulation. the continuous administration of gonadotrophin-releasing hormone agonists causes gonadotrophin suppression through down-regulation and desensitization of the gonadotrophin-releasing hormone receptors in the pituitary gland after an initial short period of gonadotrophin hypersecretion . gonadotrophin-releasing hormone antagonists (cetrorelix and ganirelix) cause immediate and rapid gonadotrophin suppression by competitive antagonism of the gonadotrophin-releasing hormone receptor in the pituitary without an initial period of gonadotrophin hypersecretion. several advantageous effects of cetrorelix were established , and these effects seemed to be independent from the type of antagonist used for luteinizing hormone-suppression.the quality of oocytes and developing preembryos is one of the most relevant factors determining the success of an in-vitro fertilization treatment. as ovarian stimulation protocol is one of the eligible factors during an in-vitro fertilization treatment, its embryo quality influencing effects are necessary to know.


Eligibility criteria:
inclusion criteria: 1. unexplained infertility. 2. tubal factor. included treated hydrosalpinx and pyosalpinx 3. first cycle . 4. body mass index: 18-29. 5. follicle stimulating hormone not more than 14 , e2 not more than 80 and antimullerian hormone \>1. 6. antral follicular count: more than 5 follicles in one ovary. 7. combined factors . 8. normal male semen analysis: mild male factor: concentrations 10 million - 20 million sperm/ml. moderate male factor : concentrations 5 million - 10 million sperm/ml. exclusion criteria: 1. patients with endometriosis. 2. azoospermic male. 3. body mass index more than 29.